A novel LMP1 antibody synergizes with mitomycin C to inhibit nasopharyngeal carcinoma growth in vivo through inducing apoptosis and downregulating vascular endothelial growth factor

International Journal of Molecular Sciences

Volumn 13, Issue 2, 2012, Pages 2208-2218

  Mao, Yuan ^a,b   Zhang, Da Wei ^a   Wen, Juan ^a   Cao, Qing ^a   Chen, Ren Jie ^a,c   Zhu, Jin ^c,d   Feng, Zhen Qing ^c  

^a THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Province Official Hospital   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

^d Huadong Medical Institute of Biotechniques   (China)

Author keywords

Antibody targeted therapy; Apoptosis; Latent membrane protein 1; Mitomycin C; Nasopharyngeal carcinoma; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 1 ANTIBODY F(AB) FRAGMENT; MITOMYCIN C; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTIBODIES; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MITOMYCIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRAL MATRIX PROTEINS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMALS; ANTAGONISTS AND INHIBITORS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG EFFECTS; DRUG SYNERGISM; HUMANS; IMMUNOLOGY; METABOLISM; MICE; MICE, INBRED BALB C; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; PATHOLOGY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

ANIMALS; ANTIBODIES; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG SYNERGISM; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOMYCIN; NASOPHARYNGEAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VIRAL MATRIX PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863262849     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13022208     Document Type: Article

References (30)

1. Chang, E.T.; Adami, H.O. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol. Biomark. Prev. 2006, 15, 1765-1777.
2. Guigay, J. Advances in nasopharyngeal carcinoma. Curr. Opin. Oncol. 2008, 20, 264-269.
3. Tao, Q.; Chan, A.T. Nasopharyngeal carcinoma: Molecular pathogenesis and therapeutic developments. Expert. Rev. Mol. Med. 2007, 9, 1-24.
4. Agulnik, M.; Epstein, J.B. Nasopharyngeal carcinoma: Current management, future directions and dental implications. Oral. Oncol. 2008, 44, 617-627.
5. Ma, B.B.; Hui, E.P.; Chan, A.T. Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: Current and future directions. Cancer Sci. 2008, 99, 1311-1318.
6. Thompson, M.P.; Kurzrock, R. Epstein-barr virus and cancer. Clin. Cancer Res. 2004, 10, 803-821.
7. Gullo, C.; Low, W.K.; Teoh, G. Association of epstein-barr virus with nasopharyngeal carcinoma and current status of development of cancer-derived cell lines. Ann. Acad. Med. 2008, 37, 769-777.
8. Krishna, S.M.; James, S.; Balaram, P. Expression of VEGF as prognosticator in primary nasopharyngeal cancer and its relation to EBV status. Virus Res. 2006, 115, 85-90.
9. Morris, M.A.; Dawson, C.W.; Young, L.S. Role of the Epstein-Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma. Future Oncol. 2009, 5, 811-825.
10. Ma, B.B.; Kam, M.K.; Leung, S.F.; Hui, E.P.; King, A.D.; Chan, S.L.; Mo, F.; Loong, H.; Yu, B.K.; Ahuja, A.; Chan, A.T. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann. Oncol. 2011, doi:10.1093/annonc/mdr401.
11. You, B. L. Tourneau, C.; Chen, E.X.; Wang, L.; Jarvi, A.; Bharadwaj, R.R.; Kamel-Reid, S.; Perez-Ordonez, B.; Mann, V.; Siu, L.L. A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma. Am. J. Clin. Oncol. 2011, doi:10.1097/COC.0b013e31820dbdcc.
12. Renjie, C.; Dawei, Z.; Yuan, M.; Jin, Z.; Hao, M.; Juan, W.; Jun, M.; Qing, C.; Hong, L.; Qi, T.; et al. A human Fab-based immunoconjugate specific for the LMP1 extracellular domain inhibits nasopharyngeal carcinoma growth in vitro and in vivo. Mol. Cancer Ther. 2011, doi:10.1158/1535-7163.MCT-11-0725.
13. Volpato, M.; Seargent, J.; Loadman, P.M.; Phillips, R.M. Formation of DNA interstrand cross-links as a marker of Mitomycin C bioreductive activation and chemosensitivity. Eur. J. Cancer. 2005, 41, 1331-1338.
14. Cao, Y.; Chen, D.; Zhao, P.; Liu, L.; Huang, X.; Qi, C.; Liu, Y.; He, H.; Wang, Q.; Liu, Y.; Chen, S. Intracellular delivery of mitomycin C with targeted polysaccharide conjugates against multidrug resistance. Ann. Biomed. Eng. 2011, 39, 2456-2465.
15. Ming, H.; Zhang, D.; Lin, H.; Chen, R.; Feng, Z.; Zhu, J. Inhibiting effect of mitomycin C on human nasopharyngeal carcinoma cell line HNE2, HNE2/lmp1 and its mechanism. J. Clin. Med. Prac. 2009, 13, 21-32.
16. Li, M.; Zhang, J.; Wang, D.; Zhong, B.; Tucker, S.; Lu, C.; Cheng, J.; Cao, C.; Xu, J.; Xu, J.; Pan, H. A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer. Anticancer 2009, 20, 941-945.
17. Xu, Y.; Kolesar, J.M.; Schaaf, L.J.; Drengler, R.; Duan, W.; Otterson, G.; Shapiro, C.; Kuhn, J.; Villalona-Calero, M.A. Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. Cancer Chemother. Pharmacol. 2009, 63, 1073-1082.
18. Lu, Z.X.; Ma, X.Q.; Yang, L.F.; Wang, Z.L.; Zeng, L.; Li, Z.J.; Li, X.N.; Tang, M.; Yi, W.; Gong, J.P.; et al. DNAzymes targeted to EBV-encoded latent membrane protein-1 induce apoptosis and enhance radiosensitivity in nasopharyngeal carcinoma. Cancer Lett. 2008, 265, 226-238.
19. Louis, C.U.; Straathof, K.; Bollard, C.M.; Gerken, C.; Huls, M.H.; Gresik, M.V.; Wu, M.F.; Weiss, H.L.; Gee, A.P.; Brenner, M.K.; et al. Enhancing the in vivo expansion of adoptively transferred EBVspecific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood 2009, 113, 2442-2450.
20. Ho, C.H.; Chen, C.L.; Li, W.Y.; Chen, C.J. Decoy receptor 3, upregulated by Epstein-Barr virus latent membrane protein 1, enhances nasopharyngeal carcinoma cell migration and invasion. Carcinogenesis 2009, 30, 1443-1451.
21. Pallis, A.G.; Agelaki, S.; Agelidou, A.; Varthalitis, I.; Syrigos, K.; Kentepozidis, N.; Pavlakou, G.; Kotsakis, A.; Kontopodis, E.; Georgoulias, V. A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer. BMC Cancer 2010, 10, doi:10.1186/ 1471-2407-10-633.
22. Akao, Y.; Nakagawa, Y.; Iinuma, M.; Nozawa, Y. Anti-cancer effects of xanthones from pericarps of mangosteen. Int. J. Mol. Sci. 2008, 9, 355-370.
23. El-Ghazal, R.; Podoltsev, N.; Marks, P.; Chu, E.; Saif, M.W. Mitomycin-C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: Cumulative toxicity of an old drug in a new era. Clin. Colorectal. Cancer 2011, 10, 142-145.
24. Zhou, Q.M.; Zhang, H.; Lu, Y.Y.; Wang, X.F.; Su, S.B. Curcumin reduced the side effects of mitomycin C by inhibiting GRP58-mediated DNA cross-linking in MCF-7 breast cancer xenografts. Cancer Sci. 2009, 100, 2040-2045.
25. Niu, G.; Wright, K.L.; Huang, M.; Song, L.; Haura, E.; Turkson, J.; Zhang, S.; Wang, T.; Sinibaldi, D.; Coppola, D.; et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21, 2000-2008.
26. Toomey, D.P.; Murphy, J.F.; Conlon, K.C. COX-2, VEGF and tumour angiogenesis. Surgeon 2009, 7, 174-180.
27. Pircher, A.; Hilbe, W.; Heidegger, I.; Drevs, J.; Tichelli, A.; Medinger, M. Biomarkers in tumor angiogenesis and anti-angiogenic therapy. Int. J. Mol. Sci. 2011, 12, 7077-7099.
28. Tan, Y.N.; Tao, Y.G.; Song, X.; Tang, M.; Ai, M.D.; Cao, Y. Expression of JAK3 in nasopharyngeal carcinoma cell line associated with STAT activation regulated by EB virus encoded protein LMP1. Prog. Biochem. Biophys. 2003, 30, 560-565.
29. Wang, Z.; Luo, F.; Li, L.; Yang, L.; Hu, D.; Ma, X.; Lu, Z.; Sun, L.; Cao, Y. STAT3 activation induced by Epstein-Barr virus latent membrane protein1 causes vascular endothelial growth factor expression and cellular invasiveness via JAK3 And ERK signaling. Eur. J. Cancer 2009, 46, 2996-3006.
30. Friedrich, M.; Villena-Heinsen, C.; Reitnauer, K.; Schmidt, W.; Tilgen, W.; Reichrath, J. Malignancies of the uterine corpus and immunoreactivity score of the DNA "mismatch-repair" enzyme human Mut-S-homologon-2. J. Histochem. Cytochem. 1999, 47, 113-118.